Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 245

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 245
---
,225)      ¥             ( 1,485)  
  Selling, general and administrative expenses      ( 75)                                          —                            ( 34)                   
  Research and development expenses                 —                                              ( 1,307)                     ( 1)                    
  Other operating expenses                          ( 1,881)                                       ( 7,923)                     ( 3,257)                
  Total                                             ¥                                ( 2,331)      ¥             ( 15,454)      ¥             ( 4,778)  

Impairment losses for the year ended March 31, 2023 resulted primarily from a decision to discontinue a production facility in Europe.

Impairment losses for the year ended March 31, 2024 resulted primarily from production facilities, whose recoverable amounts were nil, related to ALOFISEL (for complex Crohn's perianal fistulas) following topline results of the phase 3 ADMIRE-CD Ⅱ trial.

The carrying amounts of the impaired assets were reduced to the recoverable amounts, which were measured at fair value less costs of disposal. This fair value is classified as Level 3 in the fair value hierarchy.

F-37

11. Goodwill

                                                           JPY (millions)                                                           
                                                           For the Year Ended March 31                                              
                                                           2024                                            2025                     
  Acquisition cost                                                                                                                  
  As of beginning of the year                              ¥                                4,790,723      ¥             5,410,067  
  Reclassification to assets held for sale (Note 19)       ( 6,626)                                        ( 6,999)                 
  Foreign currency translation differences and others                                         625,970                    ( 78,637)  
  As of end of the year                                    ¥                                5,410,067      ¥             5,324,430  
  Carrying amount                                                                                                                   
  As of beginning of the year                              ¥                                4,790,723      ¥             5,410,067  
  As of end of the year                                                                     5,410,067                    5,324,430  

Impairment Testing of Goodwill

For the years ended March 31, 2024 and 2025, respectively, goodwill was tested for impairment at the single operating segment level ( one

For the years ended March 31, 2023, 2024 and 2025, respectively, Takeda did not record an